FDA denies Amarin's appeal

The Food and Drug Administration denied Amarin Corp.'s (Nasdaq: AMRN) appeal of the agency's recession of the ANCHOR clinical trial Special Protocol Assessment agreement sending the stock price down 40 cents to $1.41.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.